Literature DB >> 17363483

A fluorescence microplate cytotoxicity assay with a 4-log dynamic range that identifies synergistic drug combinations.

Tomas Frgala1, Ondrej Kalous, Robert T Proffitt, C Patrick Reynolds.   

Abstract

PURPOSE: Cytotoxicity assays in 96-well tissue culture plates allow rapid sample handling for multicondition experiments but have a limited dynamic range. Using DIMSCAN, a fluorescence digital image system for quantifying relative cell numbers in tissue culture plates, we have developed a 96-well cytotoxicity assay with a >4-log dynamic range.
METHODS: To overcome background fluorescence that limits detection of viable cells with fluorescein diacetate, we used 2'4'5'6'-tetrabromofluorescein (eosin Y) to quench background fluorescence in the medium and in nonviable cells to enhance the reduction of background fluorescence achieved with digital image thresholding. The sensitivity and linearity of the new assay were tested with serial dilutions of neuroblastoma and leukemia cell lines. DIMSCAN was compared with other in vitro cytotoxicity assays: 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, colony formation, and trypan blue dye exclusion.
RESULTS: Without background fluorescence reduction, scans produced a nearly flat curve across various cell concentrations from 100 to 10(6) cells per well. Either digital image thresholding or eosin Y dramatically reduced background fluorescence, and combining them achieved a linear correlation (r > 0.9) of relative fluorescence to viable cell number over >4 logs of dynamic range, even in the presence of 4 x 10(4) nonviable cells per well. Cytotoxicity of deferoxamine for neuroblastoma cell lines measured by the DIMSCAN assay achieved dose-response curves similar to data obtained by manual trypan blue counts or colony formation in soft agar but with a wider dynamic range. Long-term cultures documented the clonogenic ability of viable cells detected by DIMSCAN over the entire dynamic range. The cytotoxicity of two drug combinations (buthionine sulfoximine + melphalan or fenretinide + safingol) was tested using both DIMSCAN and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays, and the wider dynamic range of DIMSCAN facilitated detection of synergistic interactions.
CONCLUSION: DIMSCAN offers the ability to rapidly and efficiently conduct cytotoxicity assays in 96-well plates with a dynamic range of >4 logs. This assay enables rapid testing of anticancer drug combinations in microplates.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17363483     DOI: 10.1158/1535-7163.MCT-04-0331

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  64 in total

1.  National Cancer Institute pediatric preclinical testing program: model description for in vitro cytotoxicity testing.

Authors:  Min H Kang; Malcolm A Smith; Christopher L Morton; Nino Keshelava; Peter J Houghton; C Patrick Reynolds
Journal:  Pediatr Blood Cancer       Date:  2010-10-04       Impact factor: 3.167

2.  Synergistic activity of fenretinide and the Bcl-2 family protein inhibitor ABT-737 against human neuroblastoma.

Authors:  Hua Fang; Theresa M Harned; Ondrej Kalous; Vanessa Maldonado; Yves A DeClerck; C Patrick Reynolds
Journal:  Clin Cancer Res       Date:  2011-09-20       Impact factor: 12.531

3.  Novel cell lines established from pediatric brain tumors.

Authors:  Jingying Xu; Anat Erdreich-Epstein; Ignacio Gonzalez-Gomez; Elizabeth Y Melendez; Goar Smbatyan; Rex A Moats; Michael Rosol; Jaclyn A Biegel; C Patrick Reynolds
Journal:  J Neurooncol       Date:  2011-11-27       Impact factor: 4.130

4.  Initial testing (stage 1) of the cyclin dependent kinase inhibitor SCH 727965 (dinaciclib) by the pediatric preclinical testing program.

Authors:  Richard Gorlick; E Anders Kolb; Peter J Houghton; Christopher L Morton; Geoffrey Neale; Stephen T Keir; Hernan Carol; Richard Lock; Doris Phelps; Min H Kang; C Patrick Reynolds; John M Maris; Catherine Billups; Malcolm A Smith
Journal:  Pediatr Blood Cancer       Date:  2012-02-07       Impact factor: 3.167

5.  Evaluation of cytarabine against Ewing sarcoma xenografts by the pediatric preclinical testing program.

Authors:  Peter J Houghton; Christopher L Morton; Min Kang; C Patrick Reynolds; Catherine A Billups; Edward Favours; Debbie Payne-Turner; Chandra Tucker; Malcolm A Smith
Journal:  Pediatr Blood Cancer       Date:  2010-12-01       Impact factor: 3.167

6.  Expanding the Dynamic Range of Fluorescence Assays through Single-Molecule Counting and Intensity Calibration.

Authors:  Lucas Smith; Manish Kohli; Andrew M Smith
Journal:  J Am Chem Soc       Date:  2018-10-12       Impact factor: 15.419

7.  Initial testing of the investigational NEDD8-activating enzyme inhibitor MLN4924 by the pediatric preclinical testing program.

Authors:  Malcolm A Smith; John M Maris; Richard Gorlick; E Anders Kolb; Richard Lock; Hernan Carol; Stephen T Keir; C Patrick Reynolds; Min H Kang; Christopher L Morton; Jianrong Wu; Peter G Smith; Jie Yu; Peter J Houghton
Journal:  Pediatr Blood Cancer       Date:  2011-10-19       Impact factor: 3.167

8.  Initial testing of topotecan by the pediatric preclinical testing program.

Authors:  Hernan Carol; Peter J Houghton; Christopher L Morton; E Anders Kolb; Richard Gorlick; C Patrick Reynolds; Min H Kang; John M Maris; Stephen T Keir; Amy Watkins; Malcolm A Smith; Richard B Lock
Journal:  Pediatr Blood Cancer       Date:  2010-05       Impact factor: 3.167

9.  Stage 2 combination testing of rapamycin with cytotoxic agents by the Pediatric Preclinical Testing Program.

Authors:  Peter J Houghton; Christopher L Morton; Richard Gorlick; Richard B Lock; Hernan Carol; C Patrick Reynolds; Min H Kang; John M Maris; Stephen T Keir; E Anders Kolb; Jianrong Wu; Amy W Wozniak; Catherine A Billups; Larry Rubinstein; Malcolm A Smith
Journal:  Mol Cancer Ther       Date:  2010-01-06       Impact factor: 6.261

10.  Initial testing (stage 1) of the anti-microtubule agents cabazitaxel and docetaxel, by the pediatric preclinical testing program.

Authors:  C Patrick Reynolds; Min H Kang; John M Maris; E Anders Kolb; Richard Gorlick; Jianrong Wu; Raushan T Kurmasheva; Peter J Houghton; Malcolm A Smith
Journal:  Pediatr Blood Cancer       Date:  2015-07-07       Impact factor: 3.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.